Trastuzumab

GPTKB entity

Statements (64)
Predicate Object
gptkbp:instance_of gptkb:monoclonal_antibody
gptkbp:administered_by gptkb:docetaxel
gptkb:paclitaxel
gptkb:pertuzumab
gptkb:carboplatin
intravenous infusion
outpatient settings
advanced breast cancer
early breast cancer
recurrent breast cancer
HER2-positive esophageal cancer
HER2-positive gastric cancer
gptkbp:approves gptkb:1998
gptkb:FDA
gptkbp:associated_with improved survival rates
gptkbp:available_on biosimilar products
gptkbp:can_be_combined_with chemotherapy
gptkbp:can_cause hypersensitivity reactions
gptkbp:clinical_trial Phase III
gptkbp:contraindication pregnancy
severe heart failure
gptkbp:developed_by gptkb:Genentech
https://www.w3.org/2000/01/rdf-schema#label Trastuzumab
gptkbp:indication gptkb:Oncology
gptkbp:initiated_by tumor growth
gptkbp:interacts_with immune system
gptkbp:is_associated_with reduced recurrence rates
gptkbp:is_considered targeted therapy
standard of care
life-saving therapy
gptkbp:is_evaluated_by clinical trials
safety and efficacy
gptkbp:is_monitored_by cardiac function
gptkbp:is_part_of combination therapy
cancer treatment guidelines
multimodal treatment approach
breast cancer treatment protocols
HER2-targeted therapy
gptkbp:is_subject_to patent protection
gptkbp:is_used_in gptkb:guidelines
palliative care
research studies
clinical practice
gptkbp:knockouts high affinity for HER2
gptkbp:lifespan approximately 5-8 days
gptkbp:marketed_as gptkb:Herceptin
gptkbp:mechanism_of_action inhibits HER2 receptor signaling
gptkbp:produced_by Chinese hamster ovary cells
gptkbp:route_of_administration subcutaneous
gptkbp:side_effect fatigue
nausea
diarrhea
infusion reactions
cardiotoxicity
gptkbp:suitable_for HER2-negative tumors
gptkbp:targets HER2 protein
gptkbp:used_for treatment of HER2-positive breast cancer
gptkbp:used_in adjuvant therapy
neoadjuvant therapy
metastatic breast cancer
early-stage breast cancer
gptkbp:weight 148 k Da
gptkbp:bfsParent gptkb:EMD_Serono
gptkbp:bfsLayer 5